Overview

Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia

Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to find out how well participants with relapsed or refractory ALL respond to treatment with an etoposide- and teniposide-based induction chemotherapy regimen and what the side effects are. Primary Objectives: - To estimate the response rate for patients with refractory or relapsed ALL. - To estimate the survival rate of patients with refractory or relapsed ALL treated with risk-directed therapy.
Phase:
Phase 2
Details
Lead Sponsor:
St. Jude Children's Research Hospital
Treatments:
6-Mercaptopurine
Asparaginase
BB 1101
Cyclophosphamide
Cytarabine
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Etoposide
Etoposide phosphate
Mercaptopurine
Methotrexate
Mitoxantrone
Pegaspargase
Teniposide
Vinblastine
Vincristine